Santa Clara, CA - October 26th, 2015
Nanosyn, Inc. announced today a publication in the October 26th, 2015 online issue of Nature Biotechnology detailing a thorough characterization of the Published Kinase Inhibitor Set. The paper (Link) is the result of a combined effort between Nanosyn, GlaxoSmithKline, the National Institutes of Health, the European Molecular Biology Laboratory–European Bioinformatics Institute, and the Structural Genomic Consortium.
Nanosyn’s work and partnership with teams around the world culminated in the delivery of an open resource platform for academic and commercial researchers in the pre-clinical phase of drug discovery.
“Nanosyn’s comprehensive profiling platform and technology was critical in the collaboration for this publication,” said Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc. “We are thrilled to present our data and encourage scientists to explore our results when developing their next drug.”
The paper, titled Comprehensive Characterization of the Published Kinase Inhibitor Set, once again demonstrated Nanosyn commitment to continue supporting scientists in the search for new medicines.
Nanosyn (www.nanosyn.com) is a Contract Research Organization providing integrated drug discovery and development services, medicinal chemistry, made-to-order focused compound libraries, lead optimization, assay development, screening and profiling services, process chemistry, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is a privately held and self-sustaining team of expert scientists. The company is headquartered in the San Francisco Bay Area, California with discovery site in Santa Clara, CA and cGMP kilo lab in Santa Rosa, CA. For inquiries and additional information, contact Olga Issakova, Ph.D., Executive Vice President, at 650-269-3528.